RecruitingPhase 2NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nurix Therapeutics, Inc.
- Principal Investigator
- Nurix Study DirectorNurix Therapeutics, Inc.
- Intervention
- NX-5948(drug)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (18)
- Colorado Blood Institute, Denver, Colorado, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Maryland Oncology Hematology, Silver Spring, Maryland, United States
- Novant Health Cancer Institute, Winston-Salem, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Oncology Hematology Care, Fairfield, Ohio, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Texas Oncology - Center South, Austin, Texas, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- CHU de Nantes, Nantes, France
- AUSL della Romagna UO Ematologia, Ravenna, Italy
- Pratia Hematologia Sp. z o.o., Katowice, Poland
- Pratia S.A., Krakow, Poland
- Aidport Sp. z o.o., Skorzewo, Poland
- Pratia Warszawa / Pratia MTZ, Warsaw, Poland
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07221500 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn